On November 17, 2022 Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, reported that Steve Lisi, Chairman and CEO of Beyond Air, will be presenting a corporate overview and participating in 1×1 meetings at the Piper 34th Annual Healthcare Conference being held November 29 – December 1, 2022 in New York, NY (Press release, Beyond Air, NOV 17, 2022, View Source [SID1234624245]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

If you are interested in requesting a 1×1 meeting at the respective conference, please contact your bank/conference representative. For more details, please see the Events section of Beyond Air’s corporate website.